News | January 02, 2025
Akums commissions new manufacturing facility for Lyophilized and Sterile dosage
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Fluid bed processes: drying, granulating, and coating in just one product container
Our collaboration with MediSage to present 'Current Approaches to Uro-Oncology' embodies a crucial stride towards comprehensive cancer care
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Experts’ conclave to pave holistic approach to cancer management
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Subscribe To Our Newsletter & Stay Updated
